Evidence map›Paper›PMID 31305389›Full record

ArticleMedicine2019

Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis.

Chellan Kumarasamy, Madurantakam Royam Madhav, Shanthi Sabarimurugan, Kartik Lakhotiya, Venkatesh Pandey, T Priyadharshini, Siddhratha Baxi, K M Gothandam, Rama Jayaraj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Chellan KumarasamyUniversity of Adelaide, North Terrace Campus, Adelaide South Australia, Australia.
Madurantakam Royam MadhavSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Shanthi SabarimuruganSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Kartik LakhotiyaSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Venkatesh PandeySchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
T PriyadharshiniDepartment of Biochemistry, Bharathiyar University, Coimbatore, Tamil Nadu, India.
Siddhratha BaxiGenesisCare, Bunbury, Western Australia.
K M GothandamSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore.
Rama JayarajCollege of Health and Human Sciences, Charles Darwin University, Ellengowan drive, Darwin, Australia.
Vellore Institute of Technology University · INBharathiar University · INLishman Health Foundation · AUUniversity of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman epididymis protein 4 (HE4) protein has garnered a great degree of interest as a complementary biomarker to carbohydrate antigen 125 (CA125), or even as an independent biomarker for monitoring, diagnosis, and prognostication of ovarian cancer. Its use is currently limited to ovarian cancer. Recent studies have suggested that it could also be used in other types of cancers.

methodsThe Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines was used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and statistical analysis based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence interval [CIs) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If data are insufficient, a narrative line of review will be pursued. DISCUSSION: HE4 protein has been shown to have great potential for clinical use as a diagnostic and prognostic marker in epithelial ovarian cancer (EOC). However, HE4 is not only limited to expression in ovarian cancer, but is also overexpressed in lung and endometrial cancers. The effectiveness of HE4 as a biomarker in cancers (other than EOC) has not yet been studied in the form of a comprehensive systematic review and meta-analysis. The results of this study should allow for expanded use of HE4 as a multiutility biomarker in multiple cancer types, thereby, elevating HE4's value as a cancer biomarker. PROSPERO REGISTRATION: CRD42019120326.

Indexed as

Meta-Analysis as TopicSystematic Reviews as TopicBiomarkers, TumorCarcinomaHumansPrognosisProteinsResearch DesignWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, human

Identifiers

PMID31305389
PMCPMC6641664
OpenAlexW2959684828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.